Abstract library

667 results for "bone metastases".
#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Eleni Armeni
#2903 Bone Metastases (BM) in Neuroendocrine Tumors (NET): Imaging Characteristics and Clinical Implications. A Single-Institution Experience
Introduction: The incidence of BM in NET is underestimated and there is no consensus on clinical features, diagnostic techniques, and treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Valeria Smiroldo
Authors: Smiroldo V, Lania A, Pedicini V, Pepe G, ...
#2805 Small Bowel Neuroendocrine Tumor Metastases: Comparison of Contrast-Enhanced Computed Tomography and 68Ga-DOTATATE PET/CT
Introduction: Most gastrointestinal neuroendocrine tumors (GI-NETs) involve the small intestine (38%) and about 50% of patients present with regional or distant metastases at time of diagnosis [2]. 68Ga-DOTATATE PET/CT provides improved sensitivity and specificity compared to traditional nuclear medicine techniques [4]. However, there is relatively less data comparing performance of 68Ga-DOTATATE PET/CT with contrast-enhanced CT (CECT).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Hannah Monahan
#2997 Benefits of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumours: Case Reports from Two Patients with High Disease Burden
Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Jonathan Wadsley
Authors: Wadsley J, Shah T, ...
#3052 Unique Metastatic Patterns in Neuroendocrine Neoplasms of Different Primary Origin
Introduction: Neuroendocrine neoplasms (NEN) can originate in different organs, e.g. in the gastro-enteric tract (GE), pancreas (P) or lung (L). Despite similarities in clinical and pathological characteristics in tumors of another origin, differences also exist. This might apply to metastatic patterns as well, but only limited data is available so far.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Bregtje Hermans
#2733 Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours
Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke
#3022 Diagnostic Accuracy of 68Gallium Positron Emission Tomography (68Ga PET), Endoscopic Ultrasound (EUS) and Computed Tomography in the Assessment of Lymphnode Metastases by Nonfunctioning Pancreatic Neuroendocrine Neoplasms
Introduction: The presence of nodal metastasis is one of the most important predictive factors for recurrence after radical surgery for nonfunctioning Pancreatic Neuroendocrine Neoplasms (NF-PanNEN). Nevertheless, it is not clear which is the best diagnostic examination to identify preoperatively lymphnodal metastasis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr. Fabio Giannone
#2791 NEN Skeletal Metastasis Performance and the Correlation with Cell Proliferation: 112 Cases of 68Ga-DOTA-TATE Results Analysis
Introduction: 68Ga-DOTA-TATE PET/CT plays an important role in neuroendocrine neoplasm(NEN)diagnosis and biological charecteristcs evaluation.Skeleton is the second common metastatic organ in NEN after liver and it affects the quality of patient’s life.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Jiangyuan Yu
Authors: Xie Q, Lu M, Li J, Li N, ...
#2700 Pancreatic Neuroendocrine Neoplasms and Liver Metastases: When Size Matters
Introduction: Small non-functioning pNENs are low grade indolent tumors, however distant metastases have also been documented in this subset of patients
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#2815 Unexpected High Rate of Metastases in Type 1 Gastric Neuroendocrine Neoplasia
Introduction: Gastric neuroendocrine neoplasms (gNEN) represent about 7.5% of gastroenteropancreatic NEN (gepNEN), classified in: type 1 (70-80%), related to autoimmune gastritis, type 2 (5%), related to Zollinger-Ellison syndrome in multiple endocrine neoplasia 1 and type 3 (15-20%), in absence of hypergastrinemia or mucosal atrophy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Filomena Bottiglieri